EIDIA Co.

Inashiki, Japan

EIDIA Co.

Inashiki, Japan
SEARCH FILTERS
Time filter
Source Type

Patent
Eidia Co and Sekisui Medical Co. | Date: 2010-06-30

The present invention aims to provide an assay reagent and an assay for accurately measuring KL-6, in particular, an assay reagent and an assay for accurately measuring KL-6 in samples containing a rheumatoid factor and/or a nonspecific substance other than the rheumatoid factor. KL-6 in samples that contain a rheumatoid factor and/or a nonspecific substance other than the rheumatoid factor can be accurately measured using an immunoassay reagent comprising a solution at a pH of 4.0 to 5.5 containing a rheumatoid factor interference inhibitor and a solution of an insoluble carrier on which anti-KL-6 antibodies are immobilized.


Patent
Eidia Co. and Sekisui Medical Co. | Date: 2012-05-23

A problem to be solved by the present invention is to inhibit a nonspecific agglutination reaction in an agglutination test using a monoclonal antibody having a property of specifically biding to PIVKA-II and a monoclonal antibody having a property of specifically biding to prothrombin as well as two types of carrier particles carrying these monoclonal antibodies. The nonspecific agglutination reaction can be inhibited by adding certain divalent metal ions to a reaction solution containing the monoclonal antibody having a property of specifically biding to PIVKA-II and the monoclonal antibody having a property of specifically biding to prothrombin as well as the two types of carrier particles carrying these monoclonal antibodies.


Patent
Fujirebio Inc. and EIDIA Co. | Date: 2015-06-17

Disclosed are a PIVKA-II measurement method that achieves better serum-plasma correlation than conventional methods, and a reagent and a kit therefor. The PIVKA-II measurement method according to the present invention comprises measuring PIVKA-II in a sample by an immunoassay using a mixture of an anti-F1 antibody that specifically binds to prothrombin fragment F1 or an antigen-binding fragment thereof and an anti-F2 antibody that specifically binds to prothrombin fragment F2 or an antigen-binding fragment thereof; and an anti-PIVKA-II antibody that specifically binds to PIVKA-II or an antigen-binding fragment thereof.


PubMed | Osaka University, Keio University, EIDIA Co., Japan National Institute of Biomedical Innovation and 2 more.
Type: Journal Article | Journal: Journal of Crohn's & colitis | Year: 2016

Although several noninvasive and easily accessible biomarkers for inflammatory bowel disease [IBD] are available, their sensitivity and specificity are not adequate to be used as single markers and do not overrule the need for endoscopic evaluation. We previously reported that serum leucine-rich alpha-2 glycoprotein [LRG] was a novel biomarker for rheumatoid arthritis and IBD. We herein investigated whether LRG could indicate endoscopic activity in patients with ulcerative colitis [UC].Serum LRG concentrations were determined by enzyme-linked immunosorbent assay [ELISA] in consecutive 129 patients with UC in two tertiary care hospitals, and associations of LRG with clinical and endoscopic activities were evaluated. Clinical activity index [CAI] < 6 was defined as clinical remission, and mucosal healing [MH] and complete mucosal healing were defined as Matts endoscopic grades of 1 or 2 and grade of 1, respectively.Serum LRG levels were significantly increased and correlated with clinical and endoscopic activities in patients with UC. LRG levels were associated with both clinical and endoscopic activities even in patients with normal serum C-reactive protein [CRP] levels. Furthermore, LRG levels were significantly lower in patients with complete MH and deep remission. Serial measurements of LRG levels in a subset of patients demonstrated that LRG was significantly elevated during the endoscopically active stage compared with that during the MH stage.Serum LRG is a novel biomarker for detecting MH during disease course in patients with UC and a surrogate marker of endoscopic inflammation in patients with normal CRP levels.


Patent
Sekisui Medical Co. and EIDIA Co. | Date: 2014-04-09

A problem to be solved by the present invention is to inhibit a nonspecific agglutination reaction in an agglutination test using a monoclonal antibody having a property of specifically biding to PIVKA-II and a monoclonal antibody having a property of specifically biding to prothrombin as well as two types of carrier particles carrying these monoclonal antibodies. The nonspecific agglutination reaction can be inhibited by adding certain divalent metal ions to a reaction solution containing the monoclonal antibody having a property of specifically biding to PIVKA-II and the monoclonal antibody having a property of specifically biding to prothrombin as well as the two types of carrier particles carrying these monoclonal antibodies.


Patent
Sekisui Medical Co. and EIDIA Co. | Date: 2012-05-09

The present invention aims to provide an assay reagent and an assay for accurately measuring KL-6, in particular, an assay reagent and an assay for accurately measuring KL-6 in samples containing a rheumatoid factor and/or a nonspecific substance other than the rheumatoid factor. KL-6 in samples that contain a rheumatoid factor and/or a nonspecific substance other than the rheumatoid factor can be accurately measured using an immunoassay reagent comprising a solution at a pH of 4.0 to 5.5 containing a rheumatoid factor interference inhibitor and a solution of an insoluble carrier on which anti-KL-6 antibodies are immobilized.


PubMed | Uppsala University, Eisai Inc, EIDIA Co., Eisai Co. and Niigata University
Type: Journal Article | Journal: Alzheimer's & dementia (Amsterdam, Netherlands) | Year: 2016

We here examined whether plasma desmosterol-to-cholesterol ratio (DES/CHO) is decreased in patients with Alzheimers disease (AD) and investigated the association between plasma DES/CHO and longitudinal cognitive decline.Plasma DES/CHO of AD patients and age-matched controls in a Japanese cross-sectional cohort was determined. Plasma DES/CHO at baseline and follow-up visits was assessed in relation to cognitive decline in Japanese and Swedish longitudinal cohorts.Plasma DES/CHO was significantly reduced in Japanese AD patients and significantly correlated with Mini-Mental State Examination (MMSE) score. The longitudinal analysis revealed that plasma DES/CHO in AD patients shows a significant decrease at follow-up intervals. The decline in plasma DES/CHO is larger in the AD group with rapid progression than in that with slow progression. The changes in plasma DES/CHO significantly correlated with changes in the MMSE score.Plasma DES/CHO is decreased in AD patients and may serve as a longitudinal surrogate marker associated with cognitive decline.


Patent
Eidia Co. and Fujirebio Inc. | Date: 2013-08-06

Disclosed are a PIVKA-II measurement method that achieves better serum-plasma correlation than conventional methods, and a reagent and a kit therefor. The PIVKA-II measurement method according to the present invention comprises measuring PIVKA-II in a sample by an immunoassay using a mixture of an anti-F1 antibody that specifically binds to prothrombin fragment F1 or an antigen-binding fragment thereof and an anti-F2 antibody that specifically binds to prothrombin fragment F2 or an antigen-binding fragment thereof; and an anti-PIVKA-II antibody that specifically binds to PIVKA-II or an antigen-binding fragment thereof.


PubMed | Eidia Co. and Saiseikai Suita Hospital
Type: | Journal: Hepatology research : the official journal of the Japan Society of Hepatology | Year: 2016

Nonalcoholic fatty liver disease (NAFLD) can progress to nonalcoholic fatty liver (NAFL) or nonalcoholic steatohepatitis (NASH). We investigated the association among serum type IV collagen level, liver histology, and other fibrosis markers in NAFLD progression.We evaluated 184 patients diagnosed with NAFLD following biopsy, including 89 males and 95 females with an average age of 52.6 and 62.6years, respectively. NAFLD was classified as NAFL or NASH using Matteonis classification, and the grade and stage of NASH were assessed using Brunts classification. Serum type IV collagen was measured by a rapid and sensitive latex particle-enhanced turbidimetric immunoassay (LTIA).Forty-two patients with NAFL and 142 patients with NASH were included in this study. Compared with patients with NAFL, patients with NASH exhibited more significant liver function disorder and increased expression of fibrosis markers including type IV collagen, collagen 7S, Mac2-binding protein (M2BP), and hyaluronic acid (HA). Expression of type IV collagen and collagen 7S, but not M2BP and HA, was more significantly elevated in patients with stage 1 NASH than in patients with NAFL, indicating that type IV collagen and collagen 7S may be better discriminators of NASH and NAFL than M2BP and HA at an early stage of fibrosis. When patients were stratified by NAFLD activity score (NAS), type IV collagen and collagen 7S were significantly elevated as NAS progressed, whereas M2BP and HA expression were not significantly elevated.Type IV collagen may be a useful measure of NASH severity as LTIA-based rapid type IV collagen assay can be performed routinely.


PubMed | Morphotek Inc., International University of Japan, Saitama University and EIDIA Co.
Type: Journal Article | Journal: International journal of cancer | Year: 2016

Folate receptor alpha (FRA) is a GPI-anchored glycoprotein and encoded by the FOLR1 gene. High expression of FRA is observed in specific malignant tumors of epithelial origin, including ovarian cancer, but exhibits very limited normal tissue expression, making it as an attractive target for the ovarian cancer therapy. FRA is known to shed from the cell surface into the circulation which allows for its measurement in the serum of patients. Recently, methods to detect the soluble form of FRA have been developed and serum FRA (sFRA) is considered a highly promising biomarker for ovarian cancer. We prospectively investigated the levels of sFRA in patients clinically suspected of having malignant ovarian tumors. A total of 231 patients were enrolled in this study and analyzed for sFRA as well as tumor expression of FRA by immunohistochemistry. High sFRA was predominantly observed in epithelial ovarian cancer patients, but not in patients with benign or borderline gynecological disease or metastatic ovarian tumors from advanced colorectal cancers. Levels of sFRA were highly correlated to clinical stage, tumor grade and histological type and demonstrated superior accuracy for the detection of ovarian cancer than did serum CA125. High sFRA was significantly associated with shorter progression-free survival in both early and advanced ovarian cancer patients. Finally, tumor FRA expression status was strongly correlated with sFRA levels. Taken together, these data suggest that sFRA might be a useful noninvasive serum biomarkers for future clinical trials assessing FRA-targeted therapy.

Loading EIDIA Co. collaborators
Loading EIDIA Co. collaborators